Extending the use of PARP inhibitors, beyond tumors with defective BRCA1/2, ATM, CHEK2, Fanconi's Anemia genes is of great interest, expecially in prostate cancer, where mutations in DNA repair genes are rare [24]. This evidence concerns the gene BRCA1 and Fanconi anemia.